Form 4: Astria Therapeutics Director Lapointe Acquires Stock Options

Anthony Gregg Lapointe, a director of Astria Therapeutics, acquired stock options for 14,100 shares at an exercise price of $9.18 on June 5, 2024.

Summary

• On June 5, 2024, Anthony Gregg Lapointe, a director of Astria Therapeutics, Inc., was granted stock options to purchase 14,100 shares of common stock.
• The exercise price for these options is $9.18 per share.
• The options vest fully on June 4, 2025, contingent upon Lapointe's continued service as a director.
• Following this transaction, Lapointe directly owns 14,100 derivative securities.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (stock option grant) and doesn't inherently indicate positive or negative sentiment. It's a neutral event from an investment perspective.

Positives

• The acquisition of stock options by a director signals confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

This is a standard Form 4 filing, reflecting a director's acquisition of stock options, a common practice in executive compensation within the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded biotechnology companies.
• The vesting schedule of one year is fairly standard.
• Comparing the size of the grant to similar companies like BioCryst Pharmaceuticals or Ionis Pharmaceuticals would require analyzing their executive compensation disclosures.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially incentivizing value creation.

Key Dates